DCTH:NASDAQ
Delcath Systems Inc
$11.69
arrow_downward
-2.01%(-0.24) 1D
$11.69
0.00% (0.00)
bedtimePagkalipas ng oras ng trabaho
Sarado: Hun 18, 4:00:01 PM GMT-4 · USD
search
Lahat ng simbolo
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa DCTH...
Buksan
$12.09
Mataas
$12.18
Mababa
$11.64
Mkt. cap
403.56M
Avg. na dami
566.27K
Dami
582.71K
P/E ratio
1,951.59
Mataas nang 52-wk
$14.48
Mababa nang 52-wk
$8.12
EPS
$0.01
Beta
0.54
Mga natitirang share
34.52M
Bilang ng mga empleyado
156
Buksan
$12.09
Mataas
$12.18
Mababa
$11.64
Mkt. cap
403.56M
Avg. na dami
566.27K
Dami
582.71K
P/E ratio
1,951.59
Mataas nang 52-wk
$14.48
Mababa nang 52-wk
$8.12
EPS
$0.01
Beta
0.54
Mga natitirang share
34.52M
Bilang ng mga empleyado
156
Pananaw ng analyst
Mga Rating ng Analyst
Batay sa 3 (na) analyst na nagbigay ng mga rating ng stock sa DCTH sa nakalipas na 3 buwan
Strong Buy
Pagbili
3
Pag-hold
0
Pagbebenta
0
12 buwang forecast
Batay sa 3 (na) analyst sa Wall Street na nag-aalok ng mga target na presyo sa loob ng 12 buwan para sa DCTH sa nakalipas na 3 buwan.
Pinakamataas
Kasalukuyan $11.69
$30.00 (+156.63%)
Average
$25.50 (+118.14%)
Pinakamababa
$21.00 (+79.64%)
Mga balita at kwento
Mula sa mga source sa buong web
Barchart.com
·
30 minuto ang nakalipas
Is Jabil Stock Outperforming the Nasdaq?
MarketBeat
·
13 minuto ang nakalipas
Advanced Micro Devices, Inc. (NASDAQ:AMD) Given Average Recommendation of "Moderate Buy" by Analysts
Insider Monkey
·
10 oras ang nakalipas
Is nCino (NCNO) One Of The Stocks Under $20 That Will Explode?
Seeking Alpha
·
2 oras ang nakalipas
S&P 500 Snapshot: Peace Deal Overcomes Fed Jitters
Profile
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Tungkol sa Delcath Systems Inc
CEOGerard Michel
Mga Empleyado156
Itinatag1988
HeadquartersQueensbury, New York, Estados Unidos
Sektor-
Websitedelcath.com
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa